HIV Global ACCESS Program

Partnership Objective

Expand access to potentially life-saving antiretroviral medicines for patients with HIV/AIDS in low and middle-income countries, particularly in sub-Saharan Africa.

Bristol-Myers Squibb’s HIV Global ACCESS Program operates in more than 60 countries around the world. Bristol-Myers Squibb’s HIV Global ACCESS Program operates in more than 60 countries around the world. Copyright BMS

Description of partnership activities and how they address needs and challenges

Since 2000, BMS has operated a multifaceted program designed to improve access to HIV/AIDS medicines in countries that are among the most significantly impacted by the pandemic and have the fewest resources to combat it. The program rests upon three pillars:

Antiretroviral pricing that reflects no profit for the company in sub-Saharan Africa and msot low-income countries;

An HIV/AIDS medicines patent policy that reflects a commitment to access through generic manufacturer participation in sub-Saharan Africa and India;

Partnering with others who share in a commitment to the fight against HIV/AIDS.

Bristol-Myers Squibb’s HIV Global ACCESS Program operates in more than 60 countries around the world in Africa, Asia, Latin America and the Middle East. The company also offers tiered pricing for HIV/AIDS products in middle-income countries.

BMS was one of the first pharmaceutical companies to offer no-profit pricing for HIV/AIDS medicines in sub-Saharan Africa and most low income countries. In addition, BMS engages in tiered pricing in middle-income countries based on a number of factors, including affordability and government commitment to care.

Partnership information

Company(ies) Bristol-Myers Squibb

Partner(s) Clinton Foundation, Clinton Health Access Initiative, Croix Rouge Française, Crown Agents, Institute of Development Management, International Development Authority, World Bank, Medecins Sans Frontieres (MSF) / Doctors without Borders, Partnership for Supply Chain Management Development Authority, UNICEF

Type of Partner(s) Government, IGOs, Multilaterals, NGOs, Other Business, PDPs

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Differential Pricing

Targeted Population(s) Children, Elderly, General population, Men, Mothers, Patients in needs of treatment, Women, Youth

Region(s) East Asia & Pacific, Latin America & Caribbean, Middle East & North Africa, South Asia, Sub-Saharan Africa

Number of Countries 61

Country(ies) Afghanistan, Angola, Bangladesh, Benin, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Haiti, Kenya, Lao PDR, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Myanmar, Namibia, Nepal, Nicaragua, Niger, Nigeria, Pakistan, Papua New Guinea, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Solomon Islands, South Africa, South Sudan, Swaziland, Tanzania, The Gambia, Togo, Tuvalu, Uganda, Vietnam, Yemen, Zambia, Zimbabwe

Start Date 2001

More information BMS Access to Medicines

Anticipated completion date Ongoing